Trial Profile
A retrospective trial to evaluate outcomes in patients with relapsed/refractory chronic lymphocytic leukemia after ibrutinib discontinuation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2016
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology